Amplimune® Receives Canadian OMRI Listing for Use in Organic Cattle Production
The Company's regulator-approved immunotherapy for calf scours, Amplimune®, has received an Organic Materials Review Institute (OMRI) Listing in Canada. This means that Amplimune may be used in organic cattle production.
NovaVive made two presentations at the World Buiatrics Congress in Sapporo, Japan today. Both presentations highlighted efficacy of MCWF in mature dairy cattle. More research is required, but these results are very promising.
Amplimune® Receives US OMRI Listing for Use in Organic Cattle Production
Amplimune®, our immunotherapeutic for calf scours, has received an Organic Materials Review Institute (OMRI) Listing in the U.S.A. This means that Amplimune can be used in compliance with the USDA National Organic Program.
MCWF Shows Promise in Controlling Mycoplasma in Dairy Cattle
NovaVive's MCWF technology has demonstrated potential to control chronic Mycoplasma bovis (M. bovis) infection in dairy cows. M. bovis causes respiratory disease, ear infection, arthritis, mastitis, abortion and other issues.
NovaVive Signs a Co-Operation Agreement with Hoken Biotechnology to Register and Market Amplimune™ in Asia
NovaVive and Hoken Biotechnology have committed to work together to introduce Amplimune™ to Asian markets. Hoken will conduct clinical studies to support regulatory submissions and will be our sales and marketing agent.
NovaVive Presents Data Demonstrating Reduction in Antibiotic Use with MCWF in Young Calves
NovaVive today presented a Research Report at the 2017 ACVIM Forum in National Harbor, Maryland. The report summarized the results of a study conducted in a large Canadian veal operation with Amplimune™.